Featured Story | By Annalee Armstrong Pfizer reported the death of a young male patient who was participating in an an early-stage trial for the Big Pharma’s Duchenne muscular dystrophy gene therapy. The company paused screening and dosing in the study while it works with the trial site investigator to figure out what happened. read more |
| |
|---|
|
| 
| Webinar: Improving the discovery of novel drugs with artificial intelligence Thursday, February 3, 2022 | 2pm ET / 11am PT This webinar will cover the newest and most innovative AI solutions that have been developed for the life sciences industry. Topics include how AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials, best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development, and more. Register now. |
Top Stories By Nick Paul Taylor Sanofi is betting $1 billion on a preclinical pipeline of anti-cancer T-cell engagers. The upfront outlay, plus up to $225 million in milestones, is set to give Sanofi ownership of West Coast immuno-oncology player Amunix Pharmaceuticals. read more By Annalee Armstrong Senior Editor Annalee Armstrong recaps her top 10 best stories of the year produced by the Fierce Biotech team. read more By Annalee Armstrong After showing for the first time the potential of an anti-tau therapy in Alzheimer’s disease, Roche-partnered AC Immune is capitalizing on the massive moment underway in research for the neurodegenerative disease. read more By Annalee Armstrong Watch out, Sanofi and Regeneron. Eli Lilly’s Dupixent rival has posted another round of data showing improvement in atopic dermatitis when combined with topical corticosteroids in a phase 3 trial. read more By Annalee Armstrong PhaseBio is blaming the impact of COVID-19 on manufacturing for the decision to end development of a mid-stage cardiovascular disease treatment. read more By Nick Paul Taylor Cytokinetics has found another company that still sees a future for its heart failure prospect omecamtiv mecarbil. After losing partnerships with Amgen and Servier in quick succession, Cytokinetics has sold the Chinese rights to the candidate to Ji Xing Pharmaceuticals. read more By Annalee Armstrong Senti Biosciences is hopping on the SPAC track with a deal that will provide $296 million in proceeds for the preclinical biotech to move its gene circuit engineered cell and gene therapies toward human trials. read more By Annalee Armstrong The writing was perhaps on the wall for this one back in 2018: Aptose Biosciences has decided to end clinical development of the c-Myc inhibitor APTO-253, a therapy that was the subject of a three-year FDA clinical hold. read more By Kyle LaHucik Ambys Medicines wants to go after diseases impacting the liver, a key regenerative organ, with cell therapies. The Takeda-partnered biotech snagged $47 million from the Japanese Pharma and venture shops to test its asset in human trials in 2023. read more By Fraiser Kansteiner After suffering a surprise rejection from the FDA in April, Acadia Pharmaceuticals is making another bid to expand the scope of its Parkinson’s disease med Nuplazid—and it hopes to do so without running additional trials. read more By Heather Landi Global investment bank Goldman Sachs projects that the pursuit of value-based care could potentially bring significant payoff for big insurers in 2022. For the next two years, analysts Nathan Rich and Lindsay Golub estimate a potential 13% annual earnings per share growth for large-cap managed care organizations, more than double the firm’s 6% projection for S&P EPS growth, according to a recent report. read more Resources Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: BBK Worldwide New survey results and insights help clinical trial sponsors improve diversity and inclusion, enroll faster, and keep participants engaged longer. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. | 
